Two Sigma Securities’s Intellia Therapeutics NTLA Stock Holding History

Two Sigma Securities’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$328K	Buy	+19,395	New	+$271K	0.03%	808
2025 Q1	–	Sell	-13,108	Closed	-$153K	–	1976
2024 Q4	$153K	Buy	+13,108	New	+$205K	0.02%	1045
2022 Q1	–	Sell	-2,006	Closed	-$237K	–	2375
2021 Q4	$237K	Buy	+2,006	New	+$251K	0.01%	959
2021 Q3	–	Sell	-2,444	Closed	-$396K	–	1814
2021 Q2	$396K	Buy	+2,444	New	+$190K	0.01%	799

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Two Sigma Securities's NTLA Position: Q2 2026 in Review

Two Sigma Securities opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 19,395 shares worth $328K. The stake represents 0.03% of the portfolio and ranks #808 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in NTLA as recently as Q4 2024.

Two Sigma Securities first reported a position in NTLA in Q2 2021 and has held it in 4 quarters since. The position peaked at $396K in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Two Sigma Securities held 19,395 shares of Intellia Therapeutics worth $328K as of Q2 2026.
Intellia Therapeutics was a new Two Sigma Securities position in Q2 2026.
Intellia Therapeutics made up 0.03% of Two Sigma Securities's portfolio in Q2 2026, its #808 holding.
Two Sigma Securities first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 4 quarters since.
Two Sigma Securities's Intellia Therapeutics position peaked at $396K in Q2 2021.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.